$157M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global sovereign wealth fund, and Avoro Capital Advisors

Financing readies Hemab for registration studies following successful advancement of sutacimig through Phase 2 in Glanzmann thrombasthenia and continued progress of HMB-002 in Von Willebrand disease

Positions Hemab to continue expanding the clinical pipeline

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Oct. 27, 2025 — Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the completion of a multifold oversubscribed $157 million Series C financing round. The round was led by Sofinnova Partners with substantial participation from a large long-only global asset management company, and participation from additional new investors including a large global sovereign wealth fund, and Avoro Capital Advisors, alongside existing investors RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital. In connection with this financing, Joe Anderson, PhD, Partner at Sofinnova Partners, will join the Hemab Board.

Advancing Breakthrough Treatments for Glanzmann Thrombasthenia and Factor VII Deficiency

Sutacimig is being developed as the first-ever prophylactic treatment for Glanzmann thrombasthenia (GT), a serious and potentially life-threatening bleeding disorder affecting patients worldwide. The financing follows the successful completion of sutacimig’s Phase 2 study in GT with planned advancement to a registration study in 2026, alongside expanding into a Phase 2 study in Factor VII deficiency.

“As a mother of two boys with GT, I live with a constant fear, knowing from experience that a simple fall or injury can lead to a life-threatening bleed,” said Alexandra Sullivan, patient advocate and mother. “We feel so limited by the lack of effective treatments in the event of an emergency and cannot stress enough how urgently we feel the need for breakthrough treatments. Our greatest hope is to offer our children a treatment that will allow them to live normal lives. Investment in the development of modern therapies for these underserved patients brings hope to our family.”

Revolutionizing Von Willebrand Disease Treatment 

The financing also supports advancing HMB-002 towards a registration study. HMB-002 is Hemab’s antibody-based treatment with Phase 1 proof of mechanism data showing that it directly targets the underlying pathophysiology of Von Willebrand disease (VWD) by increasing both Von Willebrand Factor and Factor VIII levels. This innovative approach is designed to address the root cause of the bleeding disorder.

“For too long, people living with von Willebrand Disease have watched from the sidelines as breakthrough prophylactic therapies transformed hemophilia care,” said Jeanette Cesta, Executive Director, VWD Connect Foundation. “HMB-002 represents hope: in its potential to be the kind of innovative, patient-centered treatment our community has been waiting for. It’s time VWD patients had access to the same caliber of medicine that has already changed lives in hemophilia.”

Patients’ Insights Drive Hemab’s Innovation 

From inception, Hemab’s program development has been shaped by a portfolio of groundbreaking natural history studies including GT360, FVIID360 and VWD360, which have challenged historical assumptions and uncovered the overlooked burden of these diseases. Beyond severe, life-threatening bleeds, people face chronic pain, immobility, anxiety, depression and fatigue – yet only reactive or episodic treatments exist.

Expanding Pipeline and Building the Ultimate Clotting Company 

The additional capital enables Hemab to advance additional novel drug candidates into clinical development, with HMB-003 expected to be announced in H1 2026. This expanded pipeline reinforces Hemab’s commitment to developing comprehensive treatment solutions across the spectrum of high unmet need bleeding disorders.

“The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company,” said Benny Sorensen, MD, PhD, CEOof Hemab. “We carefully listen to people living with clotting diseases and collaborate closely with patients and families affected by these conditions and families to deliver 21st century treatment options. Hemab’s unprecedented deep domain expertise in clotting science, combined with our team’s proven capabilities in advancing programs from early development through approval and commercialization, uniquely positions us to deliver breakthrough therapies. This funding accelerates our mission of transforming lives for people who have waited far too long.”

Investor Perspectives support Growth Plans 

“Hemab’s focus on patients and an innovative approach to treating neglected bleeding disorders, combined with their deep scientific excellence and strong clinical execution, makes it a standout company in the biotech landscape,” said Joe Anderson, PhD, Partner at Sofinnova Partners. “Hemab’s progress across multiple clinical programs gives us confidence in the team’s ability to execute on their ambitious pipeline. We’re excited to support their mission to bring transformative treatments to underserved patient populations with significant medical needs.”

About Glanzmann Thrombasthenia
Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international Glanzmann’s 360 (GT360) natural history study revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week, with 34% of those bleeds requiring medical treatment. These bleeding episodes significantly impact patients’ mental health and quality of life, with 67% reporting low mood, 52% reporting emotional problems, and 46% experiencing social isolation. Additionally, 81% of participants reported missing school or work due to bruising or bleeding. To date, there are no effective prophylactic treatment options for GT.

About Sutacimig (formerly HMB-001)
Sutacimig is a subcutaneously administered bispecific antibody that binds and stabilizes endogenous Factor VIIa with one antibody arm and binds to TLT-1 on activated platelets with the other arm. This mechanism allows for the accumulation of endogenous Factor VIIa in the body and recruitment of Factor VIIa directly to the surface of the activated platelets, where it facilitates hemostatic plug formation. Sutacimig is designed to be a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT) with the potential to treat other debilitating bleeding disorders. The U.S. Food and Drug Administration granted Fast Track Designation and Orphan Drug Designation to sutacimig for the treatment of GT while the UK Medicines and Healthcare products Regulatory Agency has awarded it designation under the Innovative Licensing and Access Pathway (ILAP). For more information, please visit clinicaltrials.gov (NCT06211634).

About Von Willebrand Disease 
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying defect in VWF production or function.

About HMB-002 
HMB-002 is a monovalent human antibody being developed as the first-in-class prophylactic treatment for Von Willebrand Disease targeting the underlying root cause of the disease, a condition driven by a deficiency or defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the C-terminal CK domain of VWF, which is distinct from regions critical to its essential interactions, HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit clinicaltrials.gov (NCT06610201 and NCT06754852).

About Hemab Therapeutics 
Hemab is a multiple clinical-asset biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, and Copenhagen, Denmark, Hemab is progressing a pipeline of innovative therapeutic solutions, leveraging a variety of cutting-edge technologies and approaches to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5^TM, targets building a pipeline of development programs to deliver long-awaited innovation for people with high unmet need diseases like Glanzmann thrombasthenia, Factor VII Deficiency, Von Willebrand Disease, and others. Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Media:
Deerfield
Peg Rusconi
[email protected]

Investors:
Hemab Therapeutics
Mads Behrndt
[email protected]

SOURCE Hemab Therapeutics

– La empresa china de Robovan, Neolix, recauda más de 600 millones de dólares en la Serie D, estableciendo un nuevo récord para la industria de conducción autónoma de China

BEIJING, 27 de octubre de 2025 — Neolix, el mayor proveedor mundial de soluciones de reparto autónomo L4 (RoboVan), ha recaudado más de 600 millones de dólares en su ronda de financiación Serie D. Esta ronda supone la mayor recaudación de fondos privados en el sector de la conducción autónoma en China hasta la fecha y se encuentra entre las mayores inversiones privadas en China este año.

La ronda fue liderada por Stone Venture, con sede en los Emiratos Árabes Unidos, a la que se unieron Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capital, Beijing AI Fund y una de las plataformas de internet más grandes de China. Otros inversores clave incluyen Legend Capital, Gaorong Ventures, Templewater, SAIC, etc. Los nuevos fondos se utilizarán para impulsar los algoritmos patentados de conducción autónoma de Neolix, acelerar el desarrollo de productos en nuevos casos de uso comercial, mejorar su red de servicios y la experiencia del usuario, e impulsar sus planes de expansión global.

Fundada por Enyuan Yu, Neolix se ha consolidado rápidamente como líder mundial en vehículos autónomos de reparto desde su lanzamiento en 2018. La compañía ha entregado más de 10.000 RoboVans L4, más que cualquier otra empresa a nivel mundial, y ha alcanzado un récord de 2.000 entregas de vehículos en un solo mes. Sus vehículos se encuentran actualmente desplegados en más de 300 ciudades de China, y Qingdao alberga más de 1.200 unidades. Los populares modelos X3 y X6 de Neolix han superado las 4.000 entregas cada uno, lo que demuestra una fuerte demanda del mercado.

En el ámbito tecnológico, Neolix ha introducido importantes innovaciones, como su modelo de IA “Neolix-VA” para una navegación fluida en tráfico complejo, un sistema de conducción sin mapas para una logística urbana flexible y una plataforma de despacho inteligente que optimiza la coordinación de vehículos, carreteras y pedidos. Estos avances han ayudado a la flota de Neolix a superar los 50 millones de kilómetros de conducción autónoma.

Desde que obtuvo la primera licencia de reparto autónomo de China en 2021, Neolix ha crecido exponencialmente, alcanzando actualmente más del 60 % de la cuota de mercado en envíos acumulados y atendiendo a más de 300.000 clientes. Domina el sector del reparto exprés y se está expandiendo a servicios de alimentos frescos, cadena de frío y entrega instantánea. A nivel internacional, Neolix está expandiéndose, tras haber obtenido la primera licencia de RoboVan en los EAU en colaboración con una empresa tecnológica con sede en Abu Dabi, lo que marca su expansión global más allá de China.

Foto – https://mma.prnewswire.com/media/2803736/Neolix_secures_largest_ever_private_fundraising_China_s_autonomousdriving_industry.jpg

PEKING, 25. Oktober 2025 — Neolix, der weltweit größte Anbieter von L4-Lösungen für autonome Lieferungen (RoboVan), hat in seiner Serie-D-Finanzierungsrunde über 600 Millionen US-Dollar aufgebracht. Diese Finanzierungsrunde stellt die bislang größte private Kapitalbeschaffung im Bereich autonomes Fahren in China dar und zählt zu den bedeutendsten privaten Investitionen in China in diesem Jahr.

Die Finanzierungsrunde wurde von Stone Venture mit Sitz in den Vereinigten Arabischen Emiraten angeführt, zusammen mit Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capital, Beijing AI Fund und einer der größten Internetplattformen Chinas. Weitere wichtige Investoren sind Legend Capital, Gaorong Ventures, Templewater, SAIC usw. Die neuen Finanzmittel werden dazu verwendet, die proprietären Algorithmen für autonomes Fahren von Neolix weiterzuentwickeln, die Produktentwicklung für neue kommerzielle Anwendungsfälle zu beschleunigen, das Servicenetzwerk und die Benutzererfahrung zu verbessern sowie die globalen Expansionspläne voranzutreiben.

Neolix wurde von Herrn Enyuan Yu gegründet und hat sich seit seiner Gründung im Jahr 2018 rasch zu einem weltweit führenden Anbieter von autonomen Lieferfahrzeugen entwickelt. Das Unternehmen hat über 10.000 L4 RoboVans ausgeliefert, mehr als jedes andere Unternehmen weltweit, und in einem einzigen Monat die Rekordzahl von 2.000 Fahrzeugauslieferungen erreicht. Seine Fahrzeuge sind mittlerweile in über 300 Städten in China im Einsatz, wobei Qingdao mehr als 1.200 Einheiten beherbergt. Die beliebten Modelle X3 und X6 von Neolix haben jeweils mehr als 4.000 Auslieferungen erreicht, was die starke Nachfrage auf dem Markt verdeutlicht.

Technologisch hat Neolix bedeutende Innovationen eingeführt, darunter sein KI-Modell „Neolix-VA” für eine reibungslose Navigation im komplexen Verkehr, ein kartenloses Fahrsystem für flexible Stadtlogistik und eine intelligente Dispositionsplattform, die die Koordination von Fahrzeugen, Straßen und Aufträgen optimiert. Dank dieser Fortschritte hat die Flotte von Neolix mehr als 50 Millionen Kilometer im autonomen Fahrbetrieb zurückgelegt.

Seitdem Neolix im Jahr 2021 die erste Lizenz für autonome Lieferungen in China erhalten hat, ist das Unternehmen exponentiell gewachsen und hält nun einen Marktanteil von über 60 % bei den kumulierten Lieferungen und bedient mehr als 300.000 Kunden. Das Unternehmen ist führend im Bereich Expresslieferungen und expandiert derzeit in die Bereiche Frischwaren, Kühlketten und Sofortlieferungen. Auf internationaler Ebene expandiert Neolix und hat in Zusammenarbeit mit einem in Abu Dhabi ansässigen Technologieunternehmen die erste RoboVan-Lizenz der Vereinigten Arabischen Emirate erhalten, was seine globale Expansion über China hinaus markiert.

Foto – https://mma.prnewswire.com/media/2803736/Neolix_secures_largest_ever_private_fundraising_China_s_autonomousdriving_industry.jpg

BEIJING, 25 octobre 2025 — Neolix, le plus grand fournisseur mondial de solutions de livraison autonome de niveau 4 (RoboVan), a levé plus de 600 millions de dollars américains dans le cadre de son financement de série D. Ce tour de table représente la plus importante levée de fonds privée dans le secteur de la conduite autonome en Chine à ce jour, et figure parmi les plus gros investissements privés en Chine cette année.

Le tour de table a été mené par Stone Venture, basée aux Émirats arabes unis, rejointe par Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capital, Beijing AI Fund et l’une des principales plateformes Internet de Chine. Parmi les autres investisseurs clés figurent Legend Capital, Gaorong Ventures, Templewater et SAIC. Les nouveaux fonds seront utilisés pour faire progresser les algorithmes propriétaires de conduite autonome de Neolix, accélérer le développement de produits pour de nouveaux cas d’utilisation commerciale, améliorer son réseau de services et l’expérience des utilisateurs, et alimenter ses plans d’expansion mondiale.

Fondée par M. Enyuan Yu, Neolix s’est rapidement imposée comme un leader mondial des véhicules de livraison autonomes depuis son lancement en 2018. L’entreprise a livré plus de 10 000 RoboVans de niveau 4, soit plus que toute autre entreprise dans le monde, et a battu le record de 2 000 véhicules livrés en un seul mois. Ses véhicules sont aujourd’hui déployés dans plus de 300 villes en Chine, Qingdao accueillant plus de 1 200 unités. Les modèles populaires X3 et X6 de Neolix ont chacun dépassé les 4 000 livraisons, ce qui témoigne de la forte demande du marché.

Sur le plan technologique, Neolix a introduit des innovations majeures, notamment son modèle d’IA « Neolix-VA » pour une navigation fluide dans un trafic complexe, un système de conduite sans carte pour une logistique urbaine flexible, et une plateforme de répartition intelligente qui optimise la coordination des véhicules, des tournées et des commandes. Ces avancées ont permis à la flotte de Neolix de dépasser les 50 millions de kilomètres en conduite autonome.

Depuis qu’elle a reçu la première licence de livraison autonome de Chine en 2021, Neolix a connu une croissance exponentielle, détenant aujourd’hui plus de 60 % des parts de marché en termes de livraisons cumulées et desservant plus de 300 000 clients. Elle domine le secteur de la livraison express et se développe dans les secteurs des produits frais, de la chaîne du froid et des services de livraison instantanée. À l’échelle internationale, Neolix se développe, ayant obtenu la première licence RoboVan des Émirats arabes unis en partenariat avec une société technologique basée à Abou Dhabi, marquant ainsi son expansion mondiale au-delà de la Chine.

Photo – https://mma.prnewswire.com/media/2803736/Neolix_secures_largest_ever_private_fundraising_China_s_autonomousdriving_industry.jpg

Partnership with Bioversity International USA and Yale University will build the Rumen Digital Twin to model and optimize climate–smart feed and microbiome interventions

GREENFIELD, Ind., Oct. 24, 2025 — In partnership with Bioversity International USA and Yale University, BiomEdit, a pioneering animal health biotechnology company, announced today it has been selected as one of 15 global teams awarded funding of nearly $2 million from the Bezos Earth Fund’s AI for Climate and Nature Grand Challenge. The funding will support development of the Rumen Digital Twin, an artificial intelligence (AI) foundation model designed to identify the most effective strategies for reducing methane emissions in cattle while also optimizing animal productivity and welfare.

Together with its partners, BiomEdit will lead the effort to train a generative AI model on data from more than 20,000 ruminants across 25+ countries, including the Global South. The model will integrate publicly available and newly generated data, producing more than 10,000 microbiome profiles crosslinked with methane emissions, diet, host genetics and animal performance data.

The goal of the project is to replace lengthy and expensive animal trials with AI-powered simulations that can identify the precise conditions and animal traits where specific feed additives or interventions will be most effective. These tailored strategies are expected to reduce methane emissions by up to 75% compared to untargeted approaches, while maintaining or improving animal productivity.

“This project reflects the power of the microbiome and the use of AI to reduce methane and improve productivity in livestock,” said Aaron Schacht, CEO of BiomEdit. “With the generous support of the Bezos Earth Fund and in collaboration with Bioversity and Yale, we aim to develop a better understanding of targeted interventions and share that knowledge to positively affect both climate impact and animal well-being.”

Expected outcomes of the project include an open-access, cloud-based platform where users can generate and explore virtual ruminant populations, simulate interventions and fine-tune strategies for methane mitigation and productivity. The platform and model will be made available to research and non-profit organizations globally at no cost, with licensing pathways for commercial developers.

Launched in 2024, the Bezos Earth Fund’s AI for Climate and Nature Grand Challenge is a $100 million initiative designed to harness AI to address the dual crises of climate change and biodiversity loss. The program connects innovators with resources and mentorship from leading technology partners including AWS, Google.org, NVIDIA Corporation, Microsoft Research, AI2, and Esri.

“These projects show how AI, when developed responsibly and guided by science and local knowledge, can strengthen environmental action and ensure its overall impact on the planet is positive,” said Dr. Amen Ra Mashariki, Director of AI and Data Strategies at the Bezos Earth Fund.

The Rumen Digital Twin builds on BiomEdit’s first methane-reduction initiative: a $4.5 million grant from the Gates Foundation awarded in 2023. That program focuses on microbiome-based feed additives to reduce methane in cattle across Africa and South Asia while improving feed efficiency and food security for small-scale producers. Together, the two initiatives reflect BiomEdit’s growing leadership in developing sustainable, microbiome-based climate solutions for agriculture.

About BiomEdit
BiomEdit is an animal health microbial biotechnology company leveraging the power of the microbiome and synthetic biology to develop next-generation solutions for livestock and pet health. Founded in 2022, BiomEdit is backed by leading investors Anterra Capital, Viking Global, Nutreco, AgriZeroNZ, Elevate, and Betagro Ventures, among others. www.biomedit.com

Media Contact:
Julie Lawless
LawlessComms
[email protected]
+1 615-585-5861

SOURCE BiomEdit

SAN DIEGO, Oct. 24, 2025 — ChemDiv today announced the extension of its discovery and early development partnership with Mondego Bio to advance the company’s best-in-class immuno-oncology program targeting PTPN2. The announcement follows Mondego Bio’s successful Series A financing led by Biovance Capital with participation from OrbiMed Advisors and Torrey Pines Investment, underscoring strong momentum behind Mondego’s strategy.
ChemDiv previously supported the accelerated discovery of a drug candidate by Eilean Therapeutics LLC in the U.S., which preceded the establishment of

Mondego Bio in Portugal in 2025. Leveraging rational drug design across reversible, covalent, and allosteric inhibitors, the collaboration established a differentiated selectivity profile that delivers high oral bioavailability, robust in vivo efficacy, and strong safety and tolerability—hallmarks of potentially best-in-class cancer therapeutics.

Medicinal chemistry and scale-up were led by ChemDiv’s group in Germany, while pharmacology and translational biology were supported by ChemDiv facilities in the U.S. and Portugal. Together, these efforts advanced Mondego’s pre-IND program, supported by its European venture capital–backed launch.

Looking ahead, ChemDiv will continue to provide:

• Medicinal chemistry and discovery biology for backup series,
• CMC process research and large-scale manufacturing of the lead candidate for non-GLP and GLP animal studies,
• Computational and wet-lab pharmacology to accelerate clinical readiness.

These efforts build on ChemDiv’s deep expertise in designing selective kinase and phosphatase inhibitors, leveraging its extensive kinase and phosphatase chemical libraries, and applying parallel lead optimization supported by AI/ML-enabled rational design, ADME/DMPK, and translational capabilities.

“We’re moving fast with Mondego to translate PTPN2 biology into medicines,” said Ilya Baimetov, COO and Head of Digital Platforms at ChemDiv.
“By combining our advanced rational design, medchem horsepower, and focused tool libraries with Mondego’s cutting-edge immuno-oncology platform, we are advancing the next generation of phosphatase inhibitors with best-in-class potential.”

About Mondego Bio
Mondego Bio, headquartered at Portugal’s Biocant biotech park, is developing best-in-class PTPN2 inhibitors as a next-generation immuno-oncology strategy. The company’s Series A financing was led by Biovance Capital with co-investors OrbiMed Advisors and Torrey Pines Investment.

About ChemDiv
ChemDiv is a fully integrated discovery partner from target to clinic, offering a library of over 12 million screening compounds, 2 trillion feasible chemistries for rational drug design, thousands of pre-designed chemical tool libraries, 70,000 building blocks, and a catalog of 45,000 inhibitors and drugs. Its services include custom medicinal chemistry, CMC, AI-powered CADD, computational pharmacology, lead optimization, translational biology, and clinical pharmacology support.

For further information, please contact:

Bill Farley
CEO of ChemDiv
[email protected]

https://www.chemdiv.com/

SOURCE ChemDiv

BEIJING, Oct. 24, 2025 — Neolix, the world’s largest provider of L4 autonomous delivery (RoboVan) solutions, has raised over US$600 million in its Series D financing. This round marks the largest private fundraising in China’s autonomous driving sector to date and is among the biggest private investments in China this year.

The round was led by UAE-based Stone Venture, joined by Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capital, Beijing AI Fund and one of the largest internet platforms in China. Other key investors include Legend Capital, Gaorong Ventures, Templewater, SAIC etc. The new funds will be used to advance Neolix’s proprietary autonomous driving algorithms, accelerate product development across new commercial use cases, enhance its service network and user experience, and fuel its global expansion plans.

Founded by Mr. Enyuan Yu, Neolix has rapidly emerged as a global leader in autonomous delivery vehicles since its launch in 2018. The company has delivered over 10,000 L4 RoboVans, more than any other firm worldwide, and achieved a record-breaking 2,000 vehicle deliveries in a single month. Its vehicles are now deployed in over 300 cities in China, with Qingdao hosting more than 1,200 units. Neolix’s popular X3 and X6 models have each surpassed 4,000 deliveries, demonstrating strong market demand.

Technologically, Neolix has introduced major innovations, including its AI model “Neolix-VA” for smooth navigation in complex traffic, a map-free driving system for flexible urban logistics, and a smart dispatch platform that optimizes vehicle, road, and order coordination. These advancements have helped Neolix’s fleet surpass 50 million kilometers in autonomous driving.

Since receiving China’s first autonomous delivery license in 2021, Neolix has grown exponentially, now holding over 60% of the market share in cumulative shipments and serving more than 300,000 clients. It dominates the express delivery sector and is expanding into fresh food, cold chain, and instant delivery services. Internationally, Neolix is scaling up, having secured the UAE’s first RoboVan license in partnership with an Abu Dhabi – based Tech Company, marking its global expansion beyond China.

Photo – https://mma.prnewswire.com/media/2803736/Neolix_secures_largest_ever_private_fundraising_China_s_autonomousdriving_industry.jpg

BEIJING, Oct. 23, 2025 — Neolix, the world’s largest provider of L4 autonomous delivery (RoboVan) solutions, has raised over US$600 million in its Series D financing. By deal size, it is the largest private fundraising in China’s autonomous driving sector to date and is among the biggest private investments in China this year.

The round was led by UAE-based StoneVenture, joined by Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capital, Beijing AI Fund and one of the largest internet platforms in China. Other key investors include Legend Capital, Gaorong Ventures, Templewater, etc. Existing backer Yunqi Partners also increased its holdings, while Cygnus Equity acted as the exclusive financial advisor for the transaction.

This round marks a new chapter in Neolix’s mission to “make autonomous vehicles accessible worldwide,” underscoring strong investor confidence in the company’s technological edge and commercial momentum. Neolix plans to use the funds to further invest in algorithm and technology R&D, develop new products for diverse commercial scenarios, enhance its service network and user experience, and fuel its global expansion plans.

Neolix’s Founder and CEO, Enyuan Yu, stated that the Series D fundraising will strengthen Neolix’s technological and market leadership in autonomous intra-city logistics, accelerating large-scale commercial deployment to meet growing domestic and international demand. “We believe autonomous delivery is a key part of future urban logistics. Neolix will continue building a robust fleet, advancing visual algorithms and dispatch engines to deliver safe and efficient autonomous solutions. Our goal is to empower urban logistics with autonomous driving, making RoboVans a new productivity tool and driving digital transformation in the industry.”

Leading the RoboVan Industry Into Large-Scale Deployment

Founded by Mr. Enyuan Yu, Neolix has rapidly emerged as a global leader in autonomous delivery vehicles since its launch in 2018. The company has delivered over 10,000 L4 RoboVans, more than any other firm worldwide, and achieved a record-breaking 2,000 vehicle deliveries in a single month. Its vehicles are now deployed in over 300 cities in China, with Qingdao hosting more than 1,200 units. Neolix’s popular X3 and X6 models have each surpassed 4,000 deliveries, demonstrating strong market demand.

On the technology front, Neolix continues to pioneer breakthroughs. Its proprietary “Neolix-VA” vision-action foundation model marks the first large-scale deployment of an end-to-end model in the logistics sector, enabling RoboVans to navigate complex traffic environments through superior spatial intelligence and behavioral reasoning.

Neolix is also the first company to deploy map-free autonomous driving in freight industry , enabling true point-to-point delivery on public roads with full environmental generalization. Its AI-powered Dispatch Center integrates real-time data on vehicles, routes, and orders to optimize fleet performance. Collectively, Neolix’s L4 autonomous vehicles have accumulated over 50 million kilometers of real-world L4 driving, keeping the company far ahead of peers.

Expanding Market Share and Commercial Scenarios

Since obtaining China’s first autonomous delivery license in 2021, Neolix has experienced explosive growth. Vehicle deliveries have increased more than tenfold annually for two consecutive years. Today, the company holds over 60% of cumulative market share, 70% of new monthly shipments, and 80% of monthly revenue in China’s autonomous delivery vehicle segment, serving more than 300,000 clients ranging from large enterprises to small businesses.

In the express delivery sector, Neolix commands a leading position as the only RoboVan supplier serving all major logistics players in China, including SF Express, JD Logistics, China Post, STO, YTO, ZTO, and J&T Express, capturing nearly 70% of key account tenders.

Beyond express logistics, Neolix is rapidly expanding into fresh food, cold chain, supermarket, and urban freight scenarios, driving operational efficiency and service reliability, particularly during nighttime operations, where a single RoboVan can complete over 10 delivery cycles per shift.

Earlier this year, Neolix and Didi Freight jointly launched the world’s first RoboVan-as-a-Service (RaaS) model for on-demand logistics, significantly lowering the barrier to autonomous delivery adoption.

Orders from these diversified urban logistics scenarios now account for more than half of Neolix’s monthly order volume. In the broader urban logistics segment, Neolix currently serves hundreds of top-tier clients and commands over 60% market share.

Accelerating Global Expansion

Neolix’s success extends beyond China. In October 2025, Neolix partnered with K2 Group, an Abu Dhabi–based AI technology firm, to secure the first RoboVan license ever issued in the UAE, paving the way for scaled deployment across the Middle East. The company also joined Japan’s largest autonomous driving association, Autoware, in September 2025, and in July 2025, signed a strategic cooperation agreement with the Incheon Metropolitan Government to promote RoboVan deployment in South Korea.

Industry Outlook: 2025, the Breakout Year for Autonomous Delivery

Analysts anticipate exponential growth in autonomous delivery vehicles over the next three years. Soochow Securities forecasts that more than 30,000 units will be sold in China in 2025 alone.

Neolix estimates that China’s urban logistics market, currently served by about 30 million delivery vehicles valued at over RMB 3 trillion, is poised for large-scale automation. Within three years, major cities such as Beijing, Shanghai, and Guangzhou could each see thousands of autonomous vehicles operating daily. Once fleets reach a certain level, Neolix envisions an intelligent logistics network serving both enterprises and individuals, enabling shared capacity and highly efficient resource allocation.

Investor Endorsements

Hong Jing, Founding Partner and CEO of Gaocheng Capital:

“As an industry leader, Neolix has been at the forefront of exploring the implementation of L4 autonomous driving technology in the logistics sector and achieving Product-Market Fit. It has experienced rapid growth on the path to commercializing unmanned driving technology, serving numerous leading customers within the industry, while also demonstrating highly competitive development potential in overseas markets. As a patient growth-stage fund, we hold a highly optimistic view of China’s world-leading position in integrating hardware and software capabilities. We are committed to continuously supporting and assisting Neolix in creating value for its customers and the broader industry, consolidating its leadership position, and facilitating the global expansion of China’s cutting-edge technologies.”

Wang Lin, Founding Partner at CDH:

“Amid widening labor shortages and surging parcel volumes, Neolix’s autonomous delivery vehicles represent more than just tools, they are keys to breaking through industry bottlenecks. CDH VGC will leverage its extensive industrial resources to help Neolix integrate deeply with China’s robust supply chain ecosystem and diversified logistics scenarios, supporting its evolution from mass deployment to global ecosystem building. We aspire to be an ‘intelligent partner’ of our era, joining hands with true builders to drive industrial transformation.”

Zhao Lei, Partner at CITIC Capital:

“Our investment reflects long-term conviction in the transformative potential of smart logistics. Autonomous driving technology will fundamentally reshape the industry’s cost structure and operations. What sets Neolix apart is its ability to innovate consistently and create enduring value, which could be the strongest competitive moat. As a long-term partner, CITIC Capital will leverage deep industrial expertise to help Neolix expand new applications, accelerate technological iteration and global growth, defining the future paradigm of logistics.”

Chen Yu, Partner at Yunqi Partners:

“Since Neolix’s founding, we’ve been firm believers in its long-term potential in autonomous delivery. From the first vehicle to the ten-thousandth, the team has continuously raised the bar for the industry through solid engineering and relentless innovation in terms of algorithms, systems, and monetization. Yunqi Partners will continue to accompany Neolix on its journey, driving deeper application of autonomous driving across China’s trillion-level logistics market.”

About Neolix

Neolix is a leading provider of L4 autonomous delivery (RoboVan) solutions worldwide. Its self-developed L4 autonomous vehicles are widely deployed across express delivery, urban logistics, and other key scenarios. Guided by our mission to make autonomous vehicles accessible worldwide, Neolix has deployed over 10,000 units in 300 cities across 15 countries, covering more than 50 million kilometers of autonomous operation—among the top in the industry for both deployment scale and operational mileage.

Backed by full-stack capabilities spanning in-house software and hardware development, vehicle manufacturing, and intelligent dispatching, Neolix has filed over 1,500 patents. Designed to help clients reduce costs and enhance efficiency at scale, Neolix vehicles enable 24/7 autonomous operations—running reliably in all weather conditions, at any time of day, and across a wide range of complex road scenarios.

SOURCE Neolix

With the strategic capital from General Catalyst’s Customer Value Fund (CVF), Chainguard has secured $636 million in the last six months and $892 million in total over time

KIRKLAND, Wash., Oct. 23, 2025 — Chainguard, the trusted source for open source, today announced $280 million in growth financing from General Catalyst’s Customer Value Fund (CVF). This investment, which will help Chainguard meet growing demand and accelerate its mission to make open source software trustworthy by default, follows the company’s Series D fundraise in April and marks $636 million total secured in the past six months and $892 million in total.

The growing need for trusted open source at scale

Open source software (OSS) makes up 90% of the code organizations use today, enabling the applications and technologies these businesses rely on to deliver critical products and services. OSS has driven substantial innovation for industries globally; however, its ubiquity and use today make it a prime target for attackers. Even the smallest vulnerability can take down entire companies. As every organization races to secure its software supply chain, the demand for trustworthy, production-ready open source has reached unprecedented levels. To meet this need, Chainguard delivers hardened, secure, and production-ready builds of all the open source software engineers rely on today.

“Open source powers the world, but the way it’s delivered and deployed often introduces risk. At Chainguard, we’re flipping that script: we guard open source from all the things that can go wrong with it, so engineering teams can build anything they want with it,” said Dan Lorenc, CEO and co-founder, Chainguard. “We’re building the best, trusted source for open source. With this strategic capital, we can accelerate the adoption of Chainguard across more companies, helping engineering teams build faster, stay compliant, and eliminate risk.”

“Chainguard is defining a new category at the heart of modern infrastructure: trusted open source software. By solving one of the most pressing challenges in software development and deployment, the company is setting a new standard for engineering teams,” said Pranav Singhvi, Managing Director and Co-Head of CVF. “Dan is a standout founder who has built the business with incredible unit economics and intelligent capital allocation decisions.”

Fueling Chainguard’s next phase of go-to-market growth

Given Chainguard’s strong unit economics, the company will use this balance sheet from General Catalyst to invest in and accelerate its go-to-market scale while preserving equity dollars for investments into product, engineering and additional strategic long-term value creation. This approach enhances the company’s financial profile, supports disciplined growth, and positions Chainguard to capture a rapidly expanding market opportunity as trusted open source becomes mission-critical infrastructure for global enterprises.

“This growth capital reflects the strength of Chainguard’s business, and how we’re scaling rapidly, operating with discipline, and planning for the long term,” said Eyal Bar, Chief Financial Officer at Chainguard. “Our partnership with General Catalyst’s Customer Value Fund (CVF) is an important part of that strategy: it enables us to scale go-to-market investment without diluting ownership or slowing innovation. This structure allows our commercial motion to fund its own growth while giving us the flexibility to double down on product and engineering — where our differentiation lies, and build the operational scale and financial profile required for the next stage of growth.”

Building on continued momentum

As Chainguard scales to meet customer demand, the company has recently reached numerous milestones, including:

• Launching Chainguard Libraries for JavaScript, Java, and Python, giving organizations confidence that malware has not been inserted during the build or distribution of libraries in those ecosystems.
• Announcing Chainguard VMs, offering customers a cloud-agnostic, threat-resistant environment for deploying and running containers.
• Surpassing  1,700 minimal, zero-CVE images in its Chainguard Containers catalog, covering the majority of modern application stacks.
• Announcing availability on all major cloud provider marketplaces – Microsoft Azure, AWS, and GCP – so customers can adopt Chainguard Containers directly within their existing procurement and deployment workflows.
• Welcoming a new CISO and new CFO to support the next phase of its growth.
• Being named to the Forbes Cloud 100 and the Fortune Best Workplaces in Technology, validating its industry leadership and culture.

To learn more about Chainguard, visit www.chainguard.dev/.

About Chainguard

Chainguard is the trusted source for open source. By delivering hardened, secure, and production-ready builds of all the open source software engineers rely on, Chainguard helps organizations build faster, stay compliant, and eliminate risk. Its customers include Fortune 500 enterprises and global industry leaders, including Anduril, Canva, Fortinet, Hewlett Packard Enterprise, Snap Inc., and Snowflake. Chainguard is venture-backed by leading investors, including Amplify, IVP, Kleiner Perkins, Lightspeed Venture Partners, Mantis VC, Redpoint Ventures, Sequoia Capital, and Spark Capital. For more information, visit: https://www.chainguard.dev/

About General Catalyst

General Catalyst is a global investment and transformation company that partners with the world’s most ambitious entrepreneurs to drive resilience and applied AI.

We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond.

With offices in San Francisco, New York City, Boston, Berlin, Bangalore, and London, we have supported the growth of 800+ businesses, including Airbnb, Anduril, Applied Intuition, Commure, Glean, Guild, Gusto, Helsing, Hubspot, Kayak, Livongo, Mistral, Ramp, Samsara, Snap, Stripe, Sword, and Zepto.

For more: www.generalcatalyst.com, @generalcatalyst

SOURCE Chainguard